Guolong Pharmaceutical Guolong Pharmaceutical

Corporate email

中文/EN

简体中文

English

Hebei Guolong Pharmaceutical Co., Ltd.
Hebei Guolong Pharmaceutical Co., Ltd.
scroll down

Guolong Pharmaceutical

It is a wholly-owned subsidiary of Shijiazhuang No.4 Pharmaceutical Group (SSY Group), which is a professional API manufacturer established and developed by the group to actively promote the development strategy of "API + preparation", make full use of the advantages of the whole industry chain, adhere to the concept of "green pharmaceutical", introduce advanced equipment and green technology at home and abroad, It mainly produces bulk API azithromycin and its intermediates, hydroxyethyl starch series such as hydroxyethyl starch 40 and hydroxyethyl starch 130/0.4, moxifloxacin hydrochloride, arbidol hydrochloride, bromhexine hydrochloride and other characteristic API products.

Total land area
124913 +㎡

Covering an area of 124913.3 square meters

Active pharmaceutical ingredient
30 +

More than 30 kinds of bulk APIs and specialty APIs

View More +

Research & Development

High-end API innovation and scientific research platform

Adhering to the innovative idea of "combining imitation and innovation", we continue to increase investment in new product research and development, and create high-end innovation platforms relying on Hebei Enterprise Technology Center, Hebei Technology Innovation Center, and postdoctoral research workstations. Actively promoting the integrated innovation of production process, through over-coming key technologies such as API synthesis, we are able to develop a more refined, serialized and high-end high-value added APIs and innovative API products, so as to create a competitive advantage in variety building. 

R&D innovation

Creation of domestic bulk pharmaceutical innovation highland

Develop refined, serialized, and high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.

View More +

PRODUCTS

Azithromycin

Azithromycin

[Generic Name] Azithromycin

[Implementation Standard] Registered Standard

【Specification】25 kg/drum

Abidor Hydrochloride

Abidor Hydrochloride

[Generic Name] Arbidol Hydrochloride

[Implementation Standard] Registered Standard

[Specification] 10 kg/barrel

Bromhexine Hydrochloride

Bromhexine Hydrochloride

[Generic Name] Bromhexine Hydrochloride

[Approval Number] Y20170000261

[Implementation Standard] Registered Standard

[Specification] 1 kg/bucket

Moxifloxacin Hydrochloride

Moxifloxacin Hydrochloride

[Generic Name] Moxifloxacin Hydrochloride

[Approval Number] Y20170000871

[Implementation Standard] Registered Standard

[Specification] 5 kg/bucket

View More +

News Center

Corporate News Media reports Corporate Announcement
Li Fengshuang, Director of the Xinhua News Agency’s Hebei Branch, visited Guangxiang Pharmaceutical Group for a research visit.

Li Fengshuang, Director of the Xinhua News Agency’s Hebei Branch, visited Guangxiang Pharmaceutical Group for a research visit.

Xu Yanzeng visited Guangxiang Pharmaceutical, a subsidiary of Shijiazhuang No. 4 Pharmaceutical Group, for research and investigation.

Xu Yanzeng visited Guangxiang Pharmaceutical, a subsidiary of Shijiazhuang No. 4 Pharmaceutical Group, for research and investigation.

On March 3, Xu Yanzeng, Deputy Secretary of the Party Group and Deputy Director of the Hebei Provincial Administration for Market Regulation, as well as Party Secretary and Director of the Provincial Drug Administration, visited enterprises including Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Four Pharmaceutical Group in Cangzhou to conduct research and provide guidance on the development of the pharmaceutical industry and drug safety supervision.

2022-03-07

The grand commendation ceremony for the advanced collective of Guangxiang Pharmaceutical, part of Shijiazhuang Fourth Pharmaceutical Group, held in recognition of their outstanding achievements in boosting production has been solemnly convened.

The grand commendation ceremony for the advanced collective of Guangxiang Pharmaceutical, part of Shijiazhuang Fourth Pharmaceutical Group, held in recognition of their outstanding achievements in boosting production has been solemnly convened.

On January 3, the grand commendation ceremony for the advanced collectives of the production-boosting and challenge-accepting campaign was held at Guangxiang Pharmaceutical, a subsidiary of Shijiazhuang Fourth Pharmaceutical Group.

2022-01-20

View more+
Like! Lü Xiaolong, a post-00s employee at Guangxiang Pharmaceutical, part of Shijiazhuang Fourth Pharmaceutical Group, has successfully donated hematopoietic stem cells.

Like! Lü Xiaolong, a post-00s employee at Guangxiang Pharmaceutical, part of Shijiazhuang Fourth Pharmaceutical Group, has successfully donated hematopoietic stem cells.

2023-03-13

On the morning of February 27, in the hematopoietic stem cell collection room of the Third Hospital of Hebei Medical University, after more than five hours of collection, a young man born in the 2000s successfully donated 395 milliliters of hematopoietic stem cell suspension. These “seeds of life,” destined for distant recipients, carry with them profound love and the hope of renewed vitality. This young man from the 2000s is Lü Xiaolong, who works in the warehousing service department of Hebei Guangxiang Pharmaceutical Co., Ltd., part of Shijiazhuang Sihua Pharmaceutical Group. He is also the second employee from this group to successfully donate hematopoietic stem cells.
The “Little Giant” City Profile—Cangzhou, Hebei: Anchoring on Specialization, Excellence, and Innovation to Boost the Momentum of “Little Giants”

The “Little Giant” City Profile—Cangzhou, Hebei: Anchoring on Specialization, Excellence, and Innovation to Boost the Momentum of “Little Giants”

2022-11-13

Currently, Hebei Guangxiang Pharmaceutical Co., Ltd. has embarked on the journey to become a nationally recognized “Little Giant” enterprise specializing in niche, sophisticated, and innovative products. The company has identified untapped market segments and is poised to deepen its expertise in specialty pharmaceutical ingredients. Leveraging a series of supportive policies at the national, provincial, and municipal levels aimed at fostering the development of the biopharmaceutical industry, Guangxiang is steadily increasing its R&D investment and continuously driving its business forward to reach new heights and achieve breakthroughs.
Shi Si Yao accelerates the high-quality development of active pharmaceutical ingredients and moves toward becoming a leading API manufacturer.

Shi Si Yao accelerates the high-quality development of active pharmaceutical ingredients and moves toward becoming a leading API manufacturer.

2022-05-23

Against the backdrop of implementing the country’s new development philosophy and accelerating the transition from a major pharmaceutical producer to a powerful pharmaceutical nation, China’s leading pharmaceutical company, Shijiazhuang Fourth Pharmaceutical Group (referred to as “Shijiazhuang Fourth Pharma”), is vigorously pursuing a “API + Finished Dosage Form” development strategy. Through strategic capital partnerships, acquisitions, and restructuring, the company is actively expanding its upstream and downstream industrial chains, enhancing its competitiveness in both domestic and international markets, and injecting fresh momentum into the accelerated development of its API business segment. A series of significant initiatives are propelling Shijiazhuang Fourth Pharmaceutical Group toward its goal of becoming a leading API manufacturer.
View more+
Guangxiang Pharmaceutical Group was awarded the title of “Occupational Health Enterprise” for 2022 by Hebei Province.

2023-02-10

Guangxiang Pharmaceutical Group was awarded the title of “Occupational Health Enterprise” for 2022 by Hebei Province.

Recently, six departments—the Hebei Provincial Health Commission, the Provincial Department of Industry and Information Technology, the Provincial Department of Ecology and Environment, the Provincial Federation of Trade Unions, the Communist Youth League Hebei Provincial Committee, and the Provincial Women’s Federation—jointly released the list of “Occupational Health Enterprises” for Hebei Province in 2022. Hebei Guangxiang Pharmaceutical Co., Ltd., part of our group, was successfully included on the list and awarded the title of “Occupational Health Enterprise” by the province.
Shijiazhuang Sihua Pharmaceutical Group’s Guangxiang Pharmaceutical has been recognized as a provincial demonstration enterprise for technological innovation.

2023-01-07

Shijiazhuang Sihua Pharmaceutical Group’s Guangxiang Pharmaceutical has been recognized as a provincial demonstration enterprise for technological innovation.

On January 6, the Hebei Provincial Department of Industry and Information Technology released the list of provincial-level demonstration enterprises for technological innovation for 2022. Among them, 36 companies—including Hebei Guangxiang Pharmaceutical Co., Ltd.—were recognized by the Provincial Department of Industry and Information Technology as provincial-level demonstration enterprises for technological innovation in 2022.
Two products from Shijiazhuang Sihua Group’s Guangxiang Pharmaceutical and Guolong Pharmaceutical have been recognized as provincial manufacturing single-champion products.

2022-12-31

Two products from Shijiazhuang Sihua Group’s Guangxiang Pharmaceutical and Guolong Pharmaceutical have been recognized as provincial manufacturing single-champion products.

Recently, the Hebei Provincial Department of Industry and Information Technology released the fourth list of provincial manufacturing single-champion enterprises and single-champion products. Both Metronidazole produced by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Siyao Group, and Hydroxyethyl Starch produced by Hebei Guolong Pharmaceutical Co., Ltd. have been recognized as Hebei Province’s manufacturing single-champion products.
Shijiazhuang Sihua Pharmaceutical Group’s aggrastat active pharmaceutical ingredient has been approved.

2022-09-07

Shijiazhuang Sihua Pharmaceutical Group’s aggrastat active pharmaceutical ingredient has been approved.

Recently, the active pharmaceutical ingredient—aggrastat—submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, has been approved by the National Medical Products Administration for registration as an API intended for use in marketed formulations.
View more+

To promote the cause of human health with strength from China

Join us+